# AstraZeneca: Phase 3 study started recruiting, 1330 planned (Metastatic Hormone-Sensitive Prostate Cancer (mHSPC))

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) |
| NCT ID | NCT07711002 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| Intervention types | drug, other |
| Target enrollment | 1330 |
| Site countries | United States, Austria, Brazil, Canada, China, France, Germany, Hong Kong, Hungary, India, Italy, Japan |
| Posted | 2026-07-17 |
| Planned start | 2026-09-15 |
| Event | Started recruiting |
| Event date | 2026-09-15 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 1330 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07711002). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.